Keloid fibroblast molecular targets

Keloid fibroblast molecular targets represent a diverse group of proteins and signaling pathways that drive the pathological overgrowth of scar tissue known as keloids (PMID: 31443641). These fibroblasts exhibit a unique phenotype characterized by hyperproliferation, resistance to programmed cell death, and excessive deposition of extracellular matrix components, particularly Type I and III collagen (PMID: 28654944). Key targets include the Transforming growth factor beta (TGF-B) signaling axis, specifically TGF-B1 and its downstream Smad proteins, which are central to the fibrotic response (PMID: 31443641). Other significant targets involve growth factors like Vascular endothelial growth factor (VEGF) and Platelet-derived growth factor (PDGF), as well as intracellular pathways such as PI3K/Akt/mTOR (PMID: 25600555). Therapeutic intervention typically involves corticosteroids like Triamcinolone to reduce inflammation and collagen synthesis, or chemotherapeutic agents like 5-fluorouracil to inhibit fibroblast proliferation (StatPearls: NBK507831). Targeting these specific molecular drivers is essential for managing keloids, which are notoriously difficult to treat and prone to high recurrence rates after standard surgical excision.

Other names

Keloid-derived fibroblast targetsKeloidogenic molecular targetsFibrotic molecular targets in keloids

Inhibition of TGF-beta signaling, suppression of collagen synthesis, induction of fibroblast apoptosis, and inhibition of cell cycle progression.